4-(Difluoromethyl)-5-(4-((3R,5S)-3,5-dimethylmorpholino)-6-((R)-3-methylmorpholino)-1,3,5-triazin-2-yl)pyridin-2-amine (PQR626), a Potent, Orally Available, and Brain-Penetrant mTOR Inhibitor for the Treatment of Neurological Disorders

Chiara Borsari, Erhan Keleş, Denise Rageot, Andrea Treyer, Thomas Bohnacker, Lukas Bissegger, Martina De Pascale, Anna Melone, Rohitha Sriramaratnam, Florent Beaufils, Matthias Hamburger, Paul Hebeisen, Wolfgang Löscher, Doriano Fabbro, Petra Hillmann, Matthias P. Wymann

2020Journal of Medicinal Chemistry22 citationsDOI Open Access PDF

Abstract

as a potential therapeutic candidate for the treatment of neurological disorders.

Topics & Concepts

ChemistryTSC1PharmacophorePharmacologyPI3K/AKT/mTOR pathwayStereochemistryBiochemistrySignal transductionMedicinePI3K/AKT/mTOR signaling in cancerMast cells and histaminePolyamine Metabolism and Applications

4-(Difluoromethyl)-5-(4-((3<i>R</i>,5<i>S</i>)-3,5-dimethylmorpholino)-6-((<i>R</i>)-3-methylmorpholino)-1,3,5-triazin-2-yl)pyridin-2-amine (PQR626), a Potent, Orally Available, and Brain-Penetrant mTOR Inhibitor for the Treatment of Neurological Disorders

Abstract

Topics & Concepts